Enterprise secures EMA orphan status for CF therapy

by | 18th Nov 2026 | News

Positive phase 2 data supports ETD001 designation

Enterprise Therapeutics has been granted orphan medicinal product designation by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for ETD001, its investigational treatment for cystic fibrosis (CF).

The Brighton-based biopharmaceutical company said the designation follows positive results from a phase 2 clinical trial of ETD001, an inhaled epithelial sodium channel (ENaC) blocker designed to improve lung function by enhancing mucus clearance and reducing airway obstruction.

According to the company, the EMA COMP concluded that ETD001 met the criteria for orphan designation based on the rarity of cystic fibrosis and the therapy’s potential to deliver clinically relevant benefits. The opinion also recognised the potential of the treatment for people who are not eligible for CFTR modulator therapy.

The recommendation was supported by clinical data from the phase 2 ET-ENAC-03 study, which indicated improvements in lung function.

Orphan medicinal product designation in the EU provides a range of incentives for developers of treatments targeting rare diseases, including market exclusivity after approval.

Dr John Ford, CEO of Enterprise Therapeutics, said: “Orphan drug designation represents an important regulatory milestone for the ETD001 programme and for Enterprise Therapeutics. The decision by the EMA reflects the continued need for additional treatment options for people with cystic fibrosis, particularly those who are not able to benefit from CFTR modulators.”

He added: “We look forward to continuing the development of ETD001 in CF as well as other mucus congestion related respiratory diseases.”

Annabella Amatulli, Head of Regulatory Affairs at Enterprise Therapeutics, explained: “Our regulatory strategy supports our global development plan for ETD001, aligned with our goal to provide improved therapeutic options for people with cystic fibrosis. The EMA’s orphan drug designation further validates the strength of the programme’s scientific rationale and outcomes of the phase 2 clinical trial.”

Cystic fibrosis affects an estimated 100,000 people worldwide and is associated with reduced life expectancy. The disease is characterised by impaired mucociliary clearance and mucus congestion in the lungs, leading to recurring infection, inflammation and progressive declines in lung function.

Tags


Related posts